Hereditary Angioedema & Bradykinin-Mediated Crises
Comprehensive emergency evaluation and protocolized resuscitation of bradykinin-mediated angioedema: Hereditary Angioedema (HAE Types I, II, and normal C1-INH/Factor XII mutation), acquired C1-INH deficiency, and ACE-inhibitor-induced angioedema; fundamental pathophysiology of the contact-kinin pathway and unchecked kallikrein activity producing excessive bradykinin; differentiating bradykinin-mediated from mast-cell/histaminergic angioedema (absence of urticaria/pruritus, failure of epinephrine/steroids/antihistamines); acute laryngeal attacks and severe abdominal attacks ('bowel wall edema' mimicking surgical abdomen); targeted pharmacotherapy (Icatibant [B2 bradykinin antagonist], Ecallantide [plasma kallikrein inhibitor], plasma-derived and recombinant C1-INH concentrates [Berinert, Ruconest], Fresh Frozen Plasma); and proactive awake fiberoptic intubation.
Resuscitation Quick Actions • First 2 Minutes
Histamine vs Bradykinin
NO hives (urticaria) + NO itching (pruritus) = BRADYKININ-MEDIATED (Epinephrine, Benadryl, and Steroids DO NOT WORK!)
Airway Hair-Trigger
Laryngeal edema causes fatal asphyxiation within 1–4 hours; prepare for early awake fiberoptic intubation or surgical cricothyrotomy
C1-INH Concentrate (Berinert)
20 units/kg IV push over 10 min; directly replaces deficient/dysfunctional C1-esterase inhibitor
Icatibant (Firazyr)
30 mg Subcutaneous in abdominal wall; selective bradykinin B2 receptor antagonist; rapid relief within 30–60 minutes
Ecallantide (Kalbitor)
30 mg Subcutaneous (administered as three 10 mg injections); reversible plasma kallikrein inhibitor; risk of anaphylaxis
Abdominal HAE Attack Trap
Severe colic + ascites + bowel wall thickening on CT: it is BOWEL WALL EDEMA from HAE, NOT surgical peritonitis! Do not operate
Bottom-Line Clinical Pearl
Bradykinin-mediated angioedema (Hereditary Angioedema and ACE-inhibitor angioedema) is driven by excessive BRADYKININ, NOT histamine. The classic diagnostic clue is SWELLING WITHOUT URTICARIA OR PRURITUS. Because it is non-allergic, EPINEPHRINE, CORTICOSTEROIDS, AND ANTIHISTAMINES ARE COMPLETELY INEFFECTIVE! Laryngeal edema is the leading cause of death: maintain a hair-trigger threshold for awake fiberoptic intubation or surgical cricothyrotomy. Severe abdominal attacks present with excruciating colicky pain, vomiting, and ascites due to transient bowel wall edema on CT, often undergoing unnecessary exploratory laparotomy. Targeted rescue therapy includes: (1) C1-Esterase Inhibitor Concentrate (Berinert 20 units/kg IV), (2) Icatibant (Firazyr 30 mg SC; selective bradykinin B2 receptor antagonist), or (3) Ecallantide (Kalbitor 30 mg SC). If specialized therapies are unavailable, administer Fresh Frozen Plasma (FFP 2–4 units; contains C1-INH, though rarely can provide substrate).
Angioedema is classified into two distinct molecular mechanisms: mast-cell mediated (histaminergic) vs. bradykinin-mediated. Bradykinin is a potent nonapeptide vasodilator that binds endothelial $B_2$ bradykinin receptors, inducing rapid phosphorylation of VE-cadherin, opening inter-endothelial junctions, and triggering massive plasma extravasation into the deep dermis and submucosa.
| Condition Subtype | Enzymatic/Genetic Defect | Mechanism of Excess Bradykinin | Clinical Distinctions |
|---|---|---|---|
| HAE Type I (85%) | Quantitative deficiency of C1-esterase inhibitor ($C1\text{-INH} < 50\%$ of normal) | Unchecked activation of plasma kallikrein, which cleaves high-molecular-weight kininogen (HMWK) to generate massive amounts of free bradykinin | Autosomal dominant (SERPING1 gene); onset in childhood/adolescence; recurrent cutaneous, laryngeal, and abdominal attacks. |
| HAE Type II (15%) | Functional dysfunction of C1-esterase inhibitor (normal or elevated C1-INH protein level, but $< 50\%$ functional activity) | Identical contact pathway disinhibition | Identical presentation; diagnosis requires functional C1-INH assay. |
| ACE-Inhibitor Induced Angioedema | Pharmacological inhibition of Angiotensin-Converting Enzyme (ACE/Kininase II) by lisinopril, enalapril, ramipril | ACE is the primary enzyme responsible for the metabolic degradation and clearance of bradykinin. Inhibiting ACE causes bradykinin accumulation in tissue spaces | Occurs in 0.5–1% of patients on ACE inhibitors (5-fold higher in Black patients); can occur after years of uneventful therapy; predilection for tongue, lips, and uvula. |
| Clinical Parameter | Mast-Cell/Histaminergic Angioedema (Allergic/Anaphylaxis) | Bradykinin-Mediated Angioedema (HAE/ACE-Inhibitor) |
|---|---|---|
| Cutaneous Signs | Urticaria (hives), intense erythema, and severe pruritus (itching) | ABSENCE of urticaria; non-pruritic, non-pitting, pale/flesh-colored tissue swelling; may have serpiginous non-elevated erythema marginatum |
| Associated Features | Bronchospasm, wheezing, tachycardia, hypotension, flushing | Isolated swelling of tongue, lips, face, larynx, or severe paroxysmal abdominal pain/cramping with ascites |
| Response to Epinephrine/Steroids | Rapid, dramatic improvement to IM Epinephrine, IV Diphenhydramine, and IV Methylprednisolone | ZERO RESPONSE to epinephrine, antihistamines, or corticosteroids; continuing to administer them wastes precious airway time! |
| Medication & Class | Dosing & Administration | Mechanism & Clinical Utility |
|---|---|---|
| C1-INH Concentrate (Berinert/Cinryze/Ruconest) | Berinert: 20 units/kg IV push over 10 minutes (or Ruconest 50 units/kg IV) | Direct C1-INH replacement. Stops ongoing kallikrein activation and arrests bradykinin generation. Treatment of choice for acute HAE laryngeal attacks. |
| Icatibant (Firazyr) | 30 mg Subcutaneously in the abdominal wall (can repeat q6h; max 90 mg/24h) | Selective Bradykinin $B_2$ Receptor Antagonist. Blocks the binding of circulating bradykinin directly at endothelial receptors; rapid symptom arrest within 30–60 minutes. |
| Ecallantide (Kalbitor) | 30 mg Subcutaneously (supplied as three 10 mg [1 mL] injections) | Potent, selective reversible plasma kallikrein inhibitor. Prevents cleavage of kininogen to bradykinin. Warning: carries a 3% risk of anaphylaxis; administer only by healthcare professional with resuscitation equipment ready. |
| Fresh Frozen Plasma (FFP) | 2 to 4 units IV | Rescue option if specialized HAE drugs are unavailable. FFP contains endogenous C1-INH. Theoretical caveat: FFP also contains kininogen substrate, which rarely could transiently worsen swelling; however, clinical registries show it is overwhelmingly effective in life-threatening emergencies. |
Test Your Hereditary Angioedema & Bradykinin-Mediated Crises Clinical Acumen
Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.
Related Emergency Protocols & Differentials
Anaphylaxis & Acute Allergic Reactions
Histaminergic IgE-mediated anaphylaxis protocols.
Open Protocol Related EM ProtocolDeep Space Neck Infections & Ludwig's Angina
Submandibular swelling and awake fiberoptic airway.
Open Protocol Related EM ProtocolAirway & Rapid Sequence Intubation
Surgical cricothyrotomy and difficult airway algorithms.
Open Protocol